Novel application of edaravone

A technology of pharmaceutical excipients and ophthalmic gel, applied in the field of medicine, can solve problems such as affecting the therapeutic effect, and achieve the effects of prolonging the residence time, excellent therapeutic effect and less irritation.

Inactive Publication Date: 2018-08-17
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, cataract treatment mainly uses drugs to delay the development of cataract, and removes it through surgery when the cataract is completely opaqu...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of edaravone
  • Novel application of edaravone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The preparation of embodiment 1 Edaravone eye drops

[0016] Edaravone eye drops preparation method:

[0017] (1) Add 0.5g of sodium hyaluronate to 700ml of water for injection, and stir for 30 minutes to completely dissolve it;

[0018] (2) Add 0.5g of sodium chloride, 0.5g of sodium edetate, 0.1g of benzalkonium bromide and 0.3g of sodium bisulfite to the above-mentioned sodium hyaluronate solution, stir to dissolve, and use phosphate Adjust the pH value of the buffer to 6.8, and set the volume to 1000ml to obtain the blank matrix of eye drops;

[0019] (3) Add 0.5 g of edaravone to the blank matrix of the above-mentioned eye drops, stir well to dissolve, filter and sterilize through a 0.22 μm filter, and then pack it separately to obtain the product.

Embodiment 2

[0020] The preparation of embodiment 2 Edaravone ophthalmic gel

[0021] Edaravone ophthalmic gel prescription: Edaravone, 0.5g; Carbomer 940, 5.0g; Propylene glycol, 0.5g; Sodium bisulfite, 0.3g; Benzalkonium bromide, 0.2g; Hydrogen phosphate Disodium, sodium dihydrogen phosphate, appropriate amount; dilute to 1000g with water for injection.

[0022] Edaravone ophthalmic gel preparation method:

[0023] (1) Take 5.0 g of Carbomer 940, add 700 g of water for injection, stir evenly, let it stand still, make it swell, adjust the pH value to neutral with phosphate buffer solution, and obtain the matrix;

[0024] (2) Take another 0.5g of edaravone, 0.2g of benzalkonium bromide, 0.5g of propylene glycol, 0.3g of sodium bisulfite and water for injection and stir to form a mixture, slowly add it to the above matrix, stir evenly, and add water to 1000g, vacuum degassed, subpackaged, sterilized, ready to use.

[0025] application testing

[0026] 1. Test the protective effect of ed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of edaravone in the preparation of medicine for treating cataract and belongs to the technical field of medicine. The medicine comprises the edaravone and pharmaceutical auxiliary materials, wherein the concentration of the edaravone is 0.03-0.5%. The edaravone and the pharmaceutical auxiliary materials are prepared into eye drops and gel for the eyes, and theeye drops and gel for the eyes are good in stability, low in irritation to the eyes, capable of prolonging the staying time of the edaravone in eye tissue and capable of bringing the curative effect of the edaravone in the eye tissue into full play and have an evident better curative effect on the cataract as compared with that of current preparations for the eyes on the market.

Description

technical field [0001] The invention relates to a new application of edaravone, in particular to an application of edaravone in the preparation of medicines for preventing and treating cataract, and belongs to the technical field of medicine. Background technique [0002] Cataract is the leading blinding eye disease in the world, and about 1 / 4 of the population over the age of 65 is blind due to senile cataract. At present, cataract treatment mainly uses drugs to delay the development of cataract, and removes it through surgery when the cataract is completely opaque. However, complications such as opacity of the posterior lens capsule (post-cataract) often occur after surgery, which seriously affects its therapeutic effect. . Therefore, the development of effective cataract prevention and treatment drugs has important practical application value. [0003] The pathogenesis of cataract is relatively complicated, which is the result of long-term comprehensive effects of multi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4152A61K9/06A61K9/08A61K47/32A61K47/36A61P27/12
CPCA61K31/4152A61K9/0048A61K9/06A61K9/08A61K47/32A61K47/36A61P27/12
Inventor 张良薛梅芮佳叶晶杨召聪
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap